United States · FDA National Drug Code directory
CABOMETYX
A source-listed medicine record.
Factual source checks only. This page is not a clinically reviewed monograph. Historical or discontinued records may be included; listing does not confirm approval, current availability or pharmacy stock.
Medicine identity
- Source reference
- 42388-023_e8cdcbdc-d863-4d48-af3e-a8926b9ab017
- Product NDC
- 42388-023
- Form
- TABLET
- Composition / generic term
- cabozantinib
- Labeler
- Exelixis, Inc.
- Marketing category
- NDA
- Marketing start / end (source format)
- 20160425
- Source listing expiry
- 20261231
Source-listed ingredients
- CABOZANTINIB S-MALATE — 60 mg/1
These values do not establish equivalence or a dose recommendation.
Packages
- 30 TABLET in 1 BOTTLE (42388-023-26) · 42388-023-26
- 30 TABLET in 1 BOTTLE (42388-023-36) · 42388-023-36
- 15 TABLET in 1 BOTTLE (42388-023-37) · 42388-023-37
- 1 BOTTLE in 1 CARTON (42388-023-46) / 30 TABLET in 1 BOTTLE · 42388-023-46
- 1 BOTTLE in 1 CARTON (42388-023-57) / 15 TABLET in 1 BOTTLE · 42388-023-57
Source and coverage
Open FDA National Drug Code directory →
Snapshot retrieved: 2026-09-17. This is the acquisition date, not a medical review date.
Clinical information, images and comparisons appear only when separately reviewed for this record. Coverage may be incomplete. Ask a pharmacist or clinician about your treatment.
Browse United States records →